Titlebook: Hypercalcemia of Malignancy; F. Raue Book 1994 Springer-Verlag Berlin Heidelberg 1994 Bisphosphonate.Knochenmetastasen.Malignancy.Parathor

意見(jiàn)一致

Hypercalcemia Associated with Hematologic Malignancies0.07% in a population-based study of one million inhabitants (Mundy et al. 1980) and 1.1% in a large epidemiological study of hospital in- and outpatients performed at a major cancer hospital (Vassilopoulou-Sellin et al. 1993).

極端的正確性

Book 1994 of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.

MULTI

粗魯?shù)娜?/a>

byline

兇兆

FLASK

Drug Therapy of Hypercalcemia Due to Malignancy of malignancy are the secretion of other bone-resorbing substances by the tumor, such as 1,25-dihydroxyvitamin D, or local effects of osteolytic bone metastases (Rosol and Capen 1992; Martin and Grill 1992). The clinical features of hypercalcemia can range from asymptomatic to severe intractable na

OTHER

Isolate

不確定

E. Blindpeline to analyze the results of a set of expression experiments on a melanoma cell line that showed an over expression of miR-214 along with the modulation of a set of 73 other genes. The results suggest the presence of 27 putative regulatory modules involving ., ., ., . and 9 out of the 73 . modul